FDA-Approved Medicines vs. Cannabis Products: Exploring Modern Therapeutics
Over the past decade, cannabis-based therapeutics have rapidly transitioned from controversial alternative remedies to serious subjects of scientific and clinical investigation. As legalization expands across the United States and globally, patients are increasingly comparing conventional FDA-approved medications with cannabis products for conditions such as chronic pain, epilepsy, anxiety, neurological disorders, and cancer-related symptoms.
While cannabis has demonstrated promising therapeutic potential, significant debate remains regarding its safety, regulation, efficacy, and long-term health implications compared to standardized pharmaceutical medications.
Regulation and Standardization
One of the most important distinctions between FDA-approved medicines and dispensary cannabis products lies in regulation and standardization.
FDA-approved drugs undergo years of rigorous clinical testing before reaching the market. These medications must demonstrate safety, efficacy, pharmacokinetic consistency, and manufacturing reliability through controlled clinical trials.
According to the U.S. Food and Drug Administration (2025), approved cannabinoid-based medications such as Epidiolex, Marinol, Syndros, and Cesamet have all undergone extensive scientific evaluation to ensure consistent dosing and predictable therapeutic effects.
In contrast, all state-legal or hemp-based cannabis products sold commercially are not federally regulated and may vary widely in cannabinoid concentration, terpene composition, purity, and do not have rigorous scientific evidence to back their utility.
Support for Cannabis as a Therapeutic
Supporters of cannabis therapeutics argue that cannabis offers unique advantages over many conventional medications, particularly in chronic pain management.
McDonagh et al. (2022) found that cannabis-based products may provide modest improvements in chronic pain severity while potentially reducing reliance on opioid medications. This opioid-sparing effect has become especially relevant amid the ongoing opioid crisis in the United States.
Additionally, cannabis contains multiple cannabinoids, including tetrahydrocannabinol (THC) and cannabidiol (CBD) and others, which are thought to, but have not been proven to, interact with the endocannabinoid system in ways that may simultaneously target inflammation, pain signaling, mood, and sleep disturbances.
Unlike some single-target pharmaceutical drugs, cannabis products may produce broader multi-system therapeutic effects.
Substitution for Prescription Medications
Another growing area of research examines cannabis as a substitute for prescription medications.
Mercurio et al. (2019) conducted a qualitative study investigating why patients replace pharmaceutical medications with cannabis products. Many participants reported substituting cannabis for opioids, benzodiazepines, antidepressants, and sleep medications due to fewer perceived side effects and improved symptom management. Patients frequently described cannabis as a more natural and manageable alternative to prescription drugs, particularly for chronic pain, anxiety, and insomnia.
These findings suggest that people believe that cannabis is better for them than prescription medications despite the lack of evidence to support their views. Nonetheless, these attitudes may be helpful to improve adherence and perceived outcomes in subjective illnesses.
Accessibility and Use
Another advantage frequently associated with cannabis products is patient accessibility and perceived natural origin. Many patients report preferring cannabis over prescription medications because they perceive it as more holistic or less chemically processed.
Cannabis is also increasingly used by patients for whom conventional therapies have failed or who experience severe side effects from FDA-approved medications such as opioids, benzodiazepines, or antidepressants.
Rhee and Rosenheck (2023) reported a substantial increase in medical cannabis use among U.S. residents between 2013 and 2020, reflecting growing public confidence in cannabis-based therapies despite limited federal approval.
Dosing and Composition of Cannabis
Despite these potential benefits, substantial concerns remain regarding the widespread use of non-FDA-approved cannabis products.
One major limitation is the inconsistency in dosing and composition across products.
Unlike FDA-approved medications, cannabis flower, edibles, concentrates, and vape products may contain variable cannabinoid levels that complicate therapeutic predictability. This inconsistency increases the risk of accidental overconsumption, psychoactive adverse effects, and contamination with pesticides, heavy metals, or residual solvents.
Crowley et al. (2024) emphasized that the absence of a unified regulatory framework creates significant public health and safety concerns surrounding commercial cannabis products.
Safety Concerns of Cannabis
Safety concerns also represent a major area of debate.
Although cannabis is often perceived as safer than many pharmaceutical medications, research indicates that cannabis use may be associated with cognitive impairment, dependency risk, cardiovascular complications, anxiety, and psychosis in vulnerable individuals. THC-containing products, in particular, may impair attention, reaction time, and executive functioning.
Aebischer et al. (2022) noted that healthcare providers remain cautious regarding cannabis prescribing practices because of uncertainties surrounding long-term safety data, especially for adolescents, individuals with psychiatric disorders, and patients with cardiovascular disease.
In contrast, FDA-approved medications benefit from extensive post-market surveillance systems that continuously monitor adverse effects, drug interactions, and patient outcomes. Physicians can prescribe these medications with established dosing guidelines and evidence-based recommendations.
However, FDA-approved pharmaceuticals are not without limitations. Many conventional medications used for pain, anxiety, and neurological disorders carry risks of addiction, overdose, organ toxicity, and severe side effects. Opioids, for example, are only moderately effective for acute pain and are associated with significant addiction and mortality risks. Consequently, some researchers and clinicians argue that cannabis products may serve as safer adjunctive or alternative therapies for selected patient populations.
Need for Randomized Control Trials
The growing scientific interest in cannabis therapeutics highlights the need for additional high-quality randomized controlled trials comparing cannabis products directly to conventional pharmaceutical therapies.
Current evidence suggests that cannabis-based medicines may hold substantial therapeutic promise, particularly for chronic pain, epilepsy, chemotherapy-induced nausea, and multiple sclerosis-related spasticity.
However, the scientific literature also demonstrates that many commercially available cannabis products still lack the regulatory oversight, dosage standardization, and long-term safety validation required of FDA-approved medications.
Cannabinoid Medicine Knowledge Gap
Although concerns about cannabis safety are often emphasized, it is important to recognize that all medications, including FDA-approved pharmaceuticals, can pose significant risks if they are not prescribed, dosed, or monitored appropriately.
Safe medication use depends not only on the product itself but also on healthcare provider knowledge and patient education. Despite increasing legalization and patient interest in medical cannabis, many physicians receive limited formal education on cannabinoid therapeutics and may lack confidence in recommending appropriate products, dosing strategies, or methods of administration.
Even providers who are familiar with medical cannabis may not consistently counsel patients on dose titration, potential drug interactions, or individualized treatment plans.
This knowledge gap can increase the risk of adverse effects, ineffective treatment, or inappropriate cannabis use, highlighting the need for expanded medical education and evidence-based clinical guidelines for cannabis therapeutics.
A Balancing Act
Ultimately, the debate between FDA-approved medicines and cannabis products is not simply a question of whether one is superior to the other. Rather, it reflects a broader challenge of balancing innovation, patient autonomy, safety, and evidence-based medicine while ensuring that healthcare providers have the knowledge necessary to guide patients in the safe and effective use of all therapeutic options.
As cannabis research continues to evolve, greater integration of cannabis-derived therapeutics into mainstream healthcare will likely depend on stronger clinical evidence, improved regulation, expanded physician education, and the development of standardized clinical guidelines for prescribing and patient counseling.
References:
1. Aebischer, J. H., Dieckmann, N. F., Jones, K. D., & St John, A. W. (2022). Chronic pain clinical and prescriptive practices in the cannabis era. Pain Management Nursing, 23 (2), 109–121. [https://doi.org/10.1016/j.pmn.2021.11.009]
2. Crowley, R., Cline, K., Hilden, D., & Beachy, M. (2024). Regulatory framework for cannabis: A position paper from the American College of Physicians. Annals of Internal Medicine. [https://doi.org/10.7326/M24-0638]
3. Kansagara, D., Hill, K. P., Yost, J., et al. (2025). Cannabis or cannabinoids for the management of chronic noncancer pain: Best practice advice from the American College of Physicians. Annals of Internal Medicine. Advance online publication. [https://doi.org/10.7326/ANNALS-24-03319]
4. McDonagh, M. S., Morasco, B. J., Wagner, J., Ahmed, A. Y., Fu, R., Kansagara, D., & Chou, R. (2022). Cannabis-based products for chronic pain: A systematic review. Annals of Internal Medicine, 175 (8), 1143–1153. [https://doi.org/10.7326/M21-4520]
5. Mercurio, A., Aston, E. R., Claborn, K. R., Waye, K., & Rosen, R. K. (2019). Marijuana as a substitute for prescription medications: A qualitative study. Substance Use & Misuse, 54(11), 1894–1902. [https://doi.org/10.1080/10826084.2019.1618336]
6. Rhee, T. G., & Rosenheck, R. A. (2023). Increasing use of cannabis for medical purposes among U.S. residents, 2013–2020. American Journal of Preventive Medicine, 65 (3), 528–533. [https://doi.org/10.1016/j.amepre.2023.03.005]
7. U.S. Food and Drug Administration. (2025). FDA and cannabis: Research and drug approval process. [https://www.fda.gov/news-events/public-health-focus/fda-and-cannabis-research-and-drug-approval-process]